我们之前开发了一种针对 CTLA-4 的纳米抗体，并证明它可以在体外增强抗肿瘤 T 细胞反应；然而，将 T 细胞注射到癌症模型中后产生的反应通常很弱且短暂。在这里，我们探讨了将我们的纳米抗体与 IL-12 融合是否能够使其在暴露于未成熟树突状细胞和肿瘤细胞融合后诱导更强、更持久的 T 细胞免疫反应。融合蛋白增强了 CD8 T 细胞对肿瘤的反应在体外将 T 细胞注射到携带不同类型异种移植物的小鼠体内后，产生了更强、更持久的免疫反应。我们的体外和体内结果表明了我们的纳米抗体-白细胞介素融合系统的抗癌潜力，并支持其临床应用这种融合方法适用于各种纳米抗体。© 2024。作者。

We previously developed a nanobody targeting CTLA-4 and demonstrated that it can boost antitumour T-cell responses in vitro; however, the resulting responses after the injection of T cells into cancer models are usually weak and transient. Here, we explored whether fusing our nanobody to IL-12 would enable it to induce stronger, longer-lasting T-cell immune responses after exposure to immature dendritic cell and tumour cell fusions.The fusion protein enhanced the response of CD8+ T cells to tumour antigens in vitro and led to stronger, more persistent immune responses after the T cells were injected into mice bearing different types of xenografts.Our in vitro and in vivo results suggest the anticancer potential of our nanobody-interleukin fusion system and support the clinical application of this fusion approach for various nanobodies.© 2024. The Author(s).